Skip to content

Organon OGN Research and development expense

Research and development expense at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$3.53B+9.4%
Pfizer logo
PfizerPFE
Amgen logo
AmgenAMGN
Biogen logo
BiogenBIIB
AbbVie logo
AbbVieABBV
Viatris logo
ViatrisVTRS

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.53B-59.4%

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%
Debt / equity9.5×-7.0×
Current ratio+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organon's research and development expense?
Organon (OGN) reported research and development expense of $93M in Q1 2026.
How has Organon's research and development expense changed year-over-year?
Organon's research and development expense decreased by 3.1% year-over-year, from $96M to $93M.
What is the long-term trend for Organon's research and development expense?
Over 4 years (2021 to 2025), Organon's research and development expense has grown at a 1.9% compound annual growth rate (CAGR), from $339M to $366M.